AstraZeneca PLC (AZN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Total Revenue Chart for AstraZeneca PLC

AstraZeneca PLC (AZN) revenue for FY2025 was GBP 58.7B, a 10.9% change from FY2024. AstraZeneca PLC's revenue grew from GBP 7.3B in 1990 to GBP 58.7B in 2025 (699.3% over 35 years). Earnings per share grew from GBP 1.44 in 2000 to GBP 2.11 in 2022 (46.8%). Revenue compound annual growth rate: 5-year CAGR of 14.9%, 10-year CAGR of 9.4%, 20-year CAGR of 4.9%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (British Pounds)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
£177.73B
Implied Share Price
£114.60
Enterprise Value
£197.95B
Revenue (TTM)
£61.37B
EBITDA
£19.90B
Profit Margin
17.02%
Trailing P/E
23.15
Forward P/E
15.08
Price/Book (MRQ)
4.77
Price/Sales (TTM)
2.90
EV/EBITDA
13.12
EV/Revenue
4.35
Dividend Yield
2.76%
Book Value
£24.04
Free Cash Flow (FY2025)
£8.67B
Free Cash Flow Yield
4.88%

Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.